HC Wainwright Reiterates “Buy” Rating for Zenas BioPharma (NASDAQ:ZBIO)

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $44.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 132.80% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Guggenheim raised their price objective on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Zacks Research cut Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 21st. Finally, Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a report on Thursday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $44.29.

Zenas BioPharma Stock Performance

Shares of ZBIO opened at $18.90 on Friday. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma has a 52-week low of $8.86 and a 52-week high of $44.60. The company has a 50-day simple moving average of $21.36 and a 200-day simple moving average of $26.81. The company has a market capitalization of $1.08 billion, a PE ratio of -2.23 and a beta of -0.61.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. During the same quarter in the previous year, the company posted ($0.80) EPS. Equities research analysts predict that Zenas BioPharma will post -4.97 earnings per share for the current fiscal year.

Insider Activity

In other Zenas BioPharma news, Director Fairmount Funds Management Llc acquired 150,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was acquired at an average cost of $20.00 per share, with a total value of $3,000,000.00. Following the purchase, the director directly owned 2,359,025 shares in the company, valued at approximately $47,180,500. This trade represents a 6.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Leon O. Moulder, Jr. bought 35,000 shares of Zenas BioPharma stock in a transaction that occurred on Wednesday, April 29th. The stock was bought at an average cost of $17.62 per share, for a total transaction of $616,700.00. Following the purchase, the chief executive officer owned 1,786,039 shares in the company, valued at $31,470,007.18. This represents a 2.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 213,768 shares of company stock worth $4,137,398 over the last ninety days. 22.00% of the stock is currently owned by insiders.

Institutional Trading of Zenas BioPharma

Several institutional investors and hedge funds have recently made changes to their positions in ZBIO. SR One Capital Management LP increased its position in Zenas BioPharma by 2.6% during the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares in the last quarter. NEA Management Company LLC lifted its holdings in Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Zenas BioPharma during the fourth quarter worth about $38,402,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.